Tesofensine is a triple monoamine reuptake inhibitor that drove 9.2% weight loss at 0.5 mg/day in one phase 2 trial, but it never finished phase 3, the flagship study carries a Lancet Expression of Concern, and its ~8-9 day half-life means levels build for weeks. It is research-use-only and not FDA-approved.
What tesofensine actually is
Tesofensine (development code NS2330) is a small molecule that blocks the presynaptic reuptake of three neurotransmitters at once: dopamine, noradrenaline, and serotonin. That "triple reuptake inhibitor" mechanism is confirmed in human studies PMID: 18950853PMID: 20520602 and in rodent work PMID: 38656972. In plain terms, it leaves more of those three transmitters sitting in the synapse, which dials up satiety and energy expenditure signaling.
Here is the part most write-ups skip. Tesofensine was never designed as a diet drug. It started life as a central nervous system candidate for Parkinson's and Alzheimer's disease. It flopped on those endpoints. But across four randomized double-blind trials (740 patients on drug, 228 on placebo), people kept losing weight as a side effect, dose-dependently, with no diet program attached PMID: 18356831. The sponsor noticed, and the molecule got a second career as an obesity candidate.
So the entire weight-loss story is built on an incidental finding that someone chased. That is not disqualifying. Plenty of useful drugs were found sideways. But it sets the tone: tesofensine is a repurposed leftover, not a purpose-built, fully de-risked therapeutic.
The TIPO-1 trial: the number everyone quotes
The headline data come from one study, the phase 2 TIPO-1 trial published in The Lancet in 2008. According to PubMed, 203 obese patients were put on an energy-restricted diet and randomized to placebo or one of three tesofensine doses for 24 weeks PMID: 18950853 (DOI61525-1)).
Diet + placebo
2.0%
baseline
0.25 mg/day
4.5%
up
0.5 mg/day
9.2%
up
1.0 mg/day
10.6%
up
All three doses beat diet plus placebo at p<0.0001. The authors flagged 0.5 mg as the sweet spot: roughly double the weight loss of approved drugs at the time, with side effects that were still manageable. The 1.0 mg arm squeezed out only about 1.4 percentage points more weight loss while adding tolerability problems, so dose-stacking past 0.5 mg gave diminishing returns.
Read the trial with a caveat
The half-life problem nobody plans around
This is where tesofensine gets genuinely unusual. Its half-life is commonly reported at roughly 8-9 days (around 220 hours), among the longest of any small-molecule weight agent. I want to be straight about that number: the 8-9 day figure traces to sponsor and regulatory pharmacokinetic summaries, and I could not verify the exact "9 days" in any PubMed-indexed paper. What the published PK literature does confirm is that tesofensine undergoes enterohepatic circulation, which produces multiple plasma peaks and a prolonged apparent elimination half-life PMID: 19705923 (DOI). The drug gets reabsorbed through the gut-liver loop, which drags out how long it sticks around.
What does a multi-day half-life mean in practice? Two things, and they are inferences from the pharmacokinetics rather than a printed clinical guideline:
- Accumulation. With once-daily dosing and a half-life measured in days, plasma levels keep climbing for something like 4-6 weeks before they plateau at steady state. The dose you feel in week one is not the dose you are sitting on in week five. Effects and side effects build gradually.
- Forgiveness for missed doses, but slow correction for overshooting. Skip a single day and your blood level barely moves. That sounds convenient. The flip side is the dangerous one: if you titrate up too fast and overshoot, you cannot just stop and flush it out. You are stuck with elevated levels for over a week.
Why this argues for low and slow
Research dosing that's actually been studied
The doses with human data behind them are 0.25, 0.5, and 1.0 mg once daily, all from TIPO-1 PMID: 18950853. The 0.5 mg dose is the one judged to balance efficacy and tolerability. The 1.0 mg dose worked but added side-effect burden for marginal extra loss.
There is no validated titration schedule in the literature, because no regulator ever approved a label. Given the half-life math above, a cautious low-and-slow ramp is the defensible approach. Tesofensine is not FDA-approved for any indication, so nothing here is medical dosing advice. It is a description of what was studied. Anyone handling it should treat it as the unproven research compound it is and loop in a clinician.
Side effects: mostly GI, plus a heart-rate signal
The human side-effect profile from TIPO-1 was dominated by gastrointestinal and sleep complaints: dry mouth, nausea, constipation, hard stools, diarrhea, and insomnia PMID: 18950853. The dry mouth and constipation track with the noradrenergic and dopaminergic activity.
The cardiovascular signal is the one worth watching. At 0.25 and 0.5 mg there was no significant rise in blood pressure versus placebo, but heart rate climbed by 7.4 bpm in the 0.5 mg group (p=0.0001) PMID: 18950853. The Parkinson's/Alzheimer's meta-analysis saw the same pattern: dose-dependent heart-rate increase, no blood-pressure effect PMID: 18356831. That heart-rate bump is consistent and dose-related, so it is not noise.
It mattered enough that a later formulation, Tesomet, bolted a beta-blocker onto the molecule specifically to blunt it. Tesomet (0.5 mg tesofensine plus 50 mg metoprolol) in adults with hypothalamic obesity gave an extra 6.3% weight loss versus placebo over 24 weeks, with no significant change in heart rate or blood pressure PMID: 35294397 (DOI). The takeaway: the cardiovascular effect is real enough that researchers engineered around it.
Mood and psychiatric effects are the murkier zone. The Tesomet trial logged sleep disturbance, dry mouth, and headache, and one participant had a serious adverse event of exacerbated pre-existing anxiety PMID: 35294397. Human data on mood specifically is thin, so I would keep claims modest: insomnia is well documented, anything beyond that is a watch-this-space concern rather than a quantified risk.
One reassuring note. In 52 recreational stimulant users, tesofensine's subjective effects were no different from placebo and well below D-amphetamine, putting its abuse potential in the same low bucket as bupropion or atomoxetine PMID: 20520602 (DOI). So despite the dopamine activity, it does not read as a recreational stimulant.
How it works in the brain (rodent-level)
The mechanistic detail beyond "triple reuptake inhibitor" is preclinical. In mice and rats, tesofensine silences a subset of GABAergic neurons in the lateral hypothalamus, which dials down feeding drive, and it produced more weight loss in obese animals than lean ones PMID: 38656972 (DOI). It also blocked the body-weight rebound that usually follows weight loss. That rebound-blocking effect is interesting, because rebound is the thing that sinks most diet interventions, but it is rodent data. Do not promote it to a human claim.
Legal and RUO status
Tesofensine is not FDA-approved for obesity or anything else. It never completed phase 3 for obesity. It exists in the gray market strictly as research-use-only (RUO) material, the same regulatory bucket as most research peptides. It is not a supplement, not a prescription drug, and not for human consumption under its RUO labeling. If you see it sold as a finished weight-loss product making clinical claims, that is a red flag.
Where to buy tesofensine
If you are sourcing it for research, sourcing quality is the whole game with a niche RUO compound. We point readers to BHG Labs, which sells tesofensine as capsules (around $109.99), lot-numbered with a third-party certificate of analysis linked to each batch.
Affiliate disclosure
For the compound's full data sheet, see our tesofensine compound page.
Further reading
Frequently asked
Weekly drops, weekly research
New guides, price-drop alerts, and reader-submitted protocols. One email a week. Unsubscribe anytime.
No spam. Unsubscribe anytime.
Discussion
Sign in to join the discussion
No comments yet โ be the first to share your thoughts!